Example logo GIS 26

Global Innovation Summit 2026

6 May 2026 | Basel, Switzerland

Home
Register
Register
Register

Participants - All

Participant search result

Deputy Director of KIAT Europe

Deputy Director of KIAT Europe

Researcher (Eurostars NPC)

Seoul, South Korea

Korea Institute for Advancement of Technology (KIAT) 

Chief Executive Officer

Daegu, South Korea

AT-31 BIO Inc. 

AT-31 BIO Inc. has developed GJK-012, a patent-pending immunosuppressant for use in innovative eye drops for Sjögren's syndrome dry eye disease. We seek investors, R&D co-developers, and Big Pharma M&A/licensing partners to advance clinical trials.

AT-31 BIO Inc. has developed GJK-012, a patent-pending immunosuppressant for use in innovative eye drops for Sjögren's syndrome dry eye disease. We seek investors, R&D co-developers, and Big Pharma M&A/licensing partners to advance clinical trials.

Chief Technical Officer

Daegu, South Korea

AT-31 BIO Inc. 

Leading the paradigm shift in immunology. AT-31 BIO delivers breakthrough solutions for complex immune disorders through advanced next-generation immunosuppressive therapies.

Leading the paradigm shift in immunology. AT-31 BIO delivers breakthrough solutions for complex immune disorders through advanced next-generation immunosuppressive therapies.

CEO

Pohang, South Korea

H.MedicGear 

EUREKA Deputy HLR/ Director for International R&D Corperation

Seoul, South Korea

Korea Institute for Advancement of Technology (KIAT) 

7 results

Countries/Regions

Organisation Types

Areas of Activity

What is your business/industry sector?